Feature | Radiation Therapy | October 21, 2016 | Dave Fornell

FDA: Discontinue Use of Multidata Systems International Corp. Radiation Therapy Devices

Company has continued to produce, sell and service non-FDA cleared devices for radiation therapy

Multidata Systems International Corp, water phantom, FDA warning

October 21, 2016 — The U.S. Food and Drug Administration (FDA) issued a letter calling on radiation oncologists, medical physicists, dosimetrists and radiation therapists to stop using all medical devices manufactured and sold by Multidata Systems International Corp. The FDA said it is concerned about the risks to patients from the use of devices, which never received FDA market clearance. 

William Maisel, M.D., MPH, deputy for the Center Director for Science, Center for Devices and Radiological Health, FDA, said the agency knows of at least two Multidata medical devices that the company manufactured and distributed in the United States for which FDA never received nor reviewed 510(k) premarket notifications. These devices include: (1) accessories to radiation therapy devices including the Real Time Dosimetry (RTD) Waterphantom System; and (2) the Dual Channel Electrometer. In addition, Multidata has not registered or listed their devices with the FDA, as required by federal law.

Since 2003, Multidata has been under a Consent Decree of Permanent Injunction entered by the U.S. District Court for the Eastern District of Missouri (civil action no. 4:03cv575). Maisel said the decree prohibits Multidata from designing, manufacturing, processing, and distributing medical devices, among other restrictions. The FDA has learned, however, that Multidata manufactured and distributed medical devices in violation of the decree, including repairing and exchanging waterphantom devices for newer design models.

“The FDA is concerned that healthcare providers may be unaware of the risks associated with these devices and urges facilities to discontinue the use of any devices manufactured by Multidata,” Maisel said. He explained these need to be dispose of appropriately and replaced with accessories to radiation therapy devices and radiation treatment planning software that have been reviewed and cleared by FDA.

Analysis of the Problem

At this time, it is not known how many devices manufactured by Multidata are currently in use in hospitals and clinics throughout the United States. The FDA is not aware of adverse event reports associated with the use of Multidata's devices since Multidata has been under the decree, but because the FDA has not received or reviewed 510(k) premarket notifications, the agency is concerned about the potential risk to patients from the devices.

FDA Recommendations

In a letter to providers, Maisel urged discontinuing the use of any devices manufactured by Multidata and disposal of them appropriately. The FDA urges use of accessories to radiation therapy devices and radiation treatment planning software that have been cleared by the FDA. Registered manufacturers of these types of devices are listed under the IYE product code in the FDA’s Registration and Listing Database (www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm).

Maisel also said centers should follow quality assurance procedures to verify treatment plans by independent means, which may include manual calculations or measurements of radiation doses.

FDA Actions

Through inspections, the FDA learned that Multidata was designing, manufacturing, processing and distributing medical devices in violation of the decree. As a result, on March 3, 2016, the FDA sent a letter to Multidata ordering the firm to cease designing, manufacturing, processing, packing, repacking, labeling, installing, holding for sale and distributing any medical device. The company has now permanently ceased operations and will be dissolving.

The FDA will keep the public informed if significant new information becomes available, Maisel said. 

Related Content

DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Treatment Planning | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
Applications Open for ASRT Foundation and Canon Medical's Safety FiRsT Grant Program
News | Radiation Dose Management | May 31, 2019
The ASRT Foundation and Canon Medical Systems are now accepting applications for the 2019 Safety FiRsT grant program,...
A set of synthetic CT images created from T1 and T2 weighted MR imaging of a prostate/rectum phantom at Henry Ford Hospital. The hospital is one of the research centers developing  synthetic CT imaging for treatment planning to avoid the need for CT scans of a patient just for treatment planning purposes when they already have a more detailed soft tissue MRI exam of  the anatomy.

A set of synthetic CT images created from T1 and T2 weighted MR imaging of a prostate/rectum phantom at Henry Ford Hospital. The hospital is one of the research centers developing synthetic CT imaging for treatment planning to avoid the need for CT scans of a patient just for treatment planning purposes when they already have a more detailed soft tissue MRI exam of the anatomy.

Feature | Radiation Oncology | May 29, 2019 | By Jeff Zagoudis